Medpace has been operating in China for over 15 years in a wholly Medpace-owned central laboratory that was established since 2009. Medpace’s China laboratory has College of American Pathologists Accreditation, National Glycohemoglobin Standardization Program Level 1 Certificate, CDC-Lipid Standardization Program Certificate and Shanghai Center for Clinical Laboratory Certificate. As China is opening its pharmaceutical and clinical trial sectors, Medpace is well-positioned to help Sponsors conduct Phase I through IV clinical trials in China, including large cardiovascular outcome trials.
Medpace’s China central laboratory is conveniently located in the pharmaceutical sector of the Zhangjiang Science City, Shanghai. In 2025, the laboratory more than doubled its facility space, and has allowed Medpace to expand capabilities in order to better service our Sponsor’s clinical trials in China.
Highlights of the Shanghai Expansion:
- 1,945 Total Square Meters (SQM)
- 528 SQM for Laboratory
- 716 SQM for Logistics
- 65 SQM for Microbiology
- 167 SQM for Biorepository
Our Shanghai lab, as well as our other global laboratory locations, are wholly-owned and purpose-built with state-of-the-art infrastructure. They have the same testing instrumentation, follow global operating procedures, and utilize a global laboratory information system. Validations in the Shanghai laboratory are cross-validated with the global labs and all Medpace laboratories participate in a weekly interlaboratory correlation program to ensure perfect harmonization of global data.
Medpace China Testing Capabilities
- Safety testing, including chemistry, hematology, urinalysis, serology, and coagulation
- Biomarkers including ligand-binding (ELISA) assays, automated immunoassays, nephelometry, and lipid biomarkers (including preparative ultracentrifugation for LDL cholesterol)
- Secured 24/7/365 environmental monitored biorepository storage from ambient, refrigerated, -20°C to -80°C onsite
- Full microbiology capabilities including aerobic and anaerobic cultures, MALDI-TOF identification, and susceptibility testing
- Testing supporting trials in the following therapeutic areas: Infectious Disease, Cardiology/Vascular Diseases, Neuroscience, Endocrinology/Metabolic, Gastroenterology, Hematology/Oncology, Immunology, and Nephrology/Urology
Medpace Shanghai Team and Leadership
Medpace’s Shanghai laboratory is led by an experienced on-site Laboratory Manager and is staffed by medical technologists who have combined decades of experience in central laboratory testing. We have on-site Chinese Project Managers with deep experience in local regulations and nuances to manage studies conducted in China and are integrated into the global project management team. The laboratory also has strong leadership to manage local operations and to ensure alignment with Medpace’s global processes.
Paul Thiam Joo Tan, PhD
Senior Director, Clinical Laboratory Services
- With Medpace since 2018, 10 years managing CAP-accredited laboratories
- Former Faculty Research Associate researched on DNA vaccine eliciting T-cells immunity at The Johns Hopkins University School of Medicine, USA
- PhD in Bioinformatics
- Therapeutic area experience includes Next-Generation Sequencing in pathology and oncology, genomics, immunology, blood stem cell banking, infectious diseases and molecular diagnostics
Traci Turner, MD, MT(ASCP)
Vice-President, MRL Operations
- Global responsibility for Medpace Central Labs operations since 2011
- Diplomate, American Board of Clinical Lipidology 2013
- MD – Board Certification in Internal Medicine 2004
About Medpace’s Central Laboratories
Strategically located in the US, Belgium, China, and Singapore, Medpace’s central laboratories have the global reach and capability to conduct studies, assist with regulatory requirements, and deliver custom solutions specific to the Sponsor’s needs. All four central laboratories have the same testing instrumentation, follow global operating procedures, and utilize a global laboratory information system. New assay validations are cross-validated with the other global Medpace laboratories and all participate in a weekly interlaboratory correlation program to ensure perfect harmonization of global data.
Medpace provides customized, high-quality central laboratory services to pharmaceutical and biotech clinical development industries. Our four wholly-owned laboratories offer full-service support to six continents for phase I-IV studies. We have extensive experience from small and simple clinical trials to those that are large, global, and complex.
Our wholly-owned global laboratory facilities, standardized testing platforms, comprehensive test menu, and stellar project management teams allow Medpace to set up fully customized projects for our clients. Combined with Medpace Clinical Research Organization expertise, we provide a fully integrated seamless solution for your clinical development needs.
Learn more about Medpace’s central laboratories.